You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: April 4, 2025

CLINICAL TRIALS PROFILE FOR TRIAMCINOLONE ACETONIDE


✉ Email this page to a colleague

« Back to Dashboard


505(b)(2) Clinical Trials for TRIAMCINOLONE ACETONIDE

This table shows clinical trials for potential 505(b)(2) applications. See the next table for all clinical trials
Trial TypeTrial IDTitleStatusSponsorPhaseStart DateSummary
New Formulation NCT00071227 ↗ Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders Completed National Eye Institute (NEI) Phase 1 2003-10-15 This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.
>Trial Type>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 1 of 1 entries

All Clinical Trials for TRIAMCINOLONE ACETONIDE

Trial IDTitleStatusSponsorPhaseStart DateSummary
NCT00071227 ↗ Eye Injections of Triamcinolone Acetonide for Retinal Blood Vessel Disorders Completed National Eye Institute (NEI) Phase 1 2003-10-15 This study will evaluate the safety and effectiveness of a new formulation of triamcinolone acetonide for the treatment of retinal blood vessel disorders. Triamcinolone is a steroid drug that decreases inflammation and scarring and is routinely used to treat eye inflammation or swelling. The commercially available form of this drug is associated with potentially harmful side effects thought to be due to preservatives in the preparation. This study will use a formulation that does not contain these potentially harmful preservatives. Preliminary findings from other studies suggest that injection of steroids in the eye can reduce retinal thickening and improve vision. However, they may also cause mild discomfort and lead to vision-threatening conditions. The effects of the drug on the conditions under study in this protocol are not known. Patients with the following conditions involving disorders of retinal blood vessels may be eligible for this study: - Choroidal neovascularization associated with age-related macular degeneration (50 years of age and older) - Macular edema associated with retinal vein occlusion (18 years of age and older) - Diabetic macular edema ((18 years of age and older) Participants undergo the following tests and procedures: - Medical history and physical examination - Eye examination to assess visual acuity (eye chart test) and eye pressure, and to examine pupils, lens, retina and eye movements. The pupils will be dilated with drops for this examination. - Fluorescein angiography to evaluate the eye's blood vessels. A yellow dye is injected into an arm vein and travels to the blood vessels in the eyes. Pictures of the retina are taken using a camera that flashes a blue light into the eye. The pictures show if any dye has leaked from the vessels into the retina, indicating possible blood vessel abnormality. - Indocyanine green angiography to identify feeder vessels that may be supplying abnormal blood vessels. This procedure is similar to fluorescein angiography, but uses a green dye and flashes an invisible light. - Optical coherence tomography to measure retinal thickness. This test shines a light into the eye and produces cross-sectional pictures of the retina. These measurements are repeated during the study to determine if retinal thickening is getting better or worse, or staying the same. - Stereoscopic color fundus photography to examine the back of the eye. The pupils are dilated with eye drops to allow examination and photography of the back of the eye. - Triamcinolone acetonide injection to treat the eye. A numbing eye drop, an antibiotic eye drop, and an injected antibiotic are put in the eye before triamcinolone acetonide is injected into the eye's vitreous (jelly-like substance inside the eye). After the injection, the patient lies on his or her back for 30 minutes. An antibiotic eye ointment is used for 2 days following treatment. - Blood tests to measure liver and kidney function. Patients return to the clinic for follow-up visits 1, 4, and 7 days, and 1 month after the first treatment. Patients whose condition does not improve after 3 months do not receive any more injections, but return for eye examinations at least once a year for 3 years. Patients whose condition improves with treatment return for follow-up visits 6 and 9 months after the first injection and then every 6 months for 2 more years. At each visit, a determination is made whether another injection is needed. After each repeat injection, patients return for follow-up visits at 1, 4, and 7 days after the injection.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
NCT00000577 ↗ Asthma Clinical Research Network (ACRN) Withdrawn Milton S. Hershey Medical Center Phase 3 1993-09-01 This study will establish a network of interactive asthma clinical research groups to evaluate current therapies, new therapies, and management strategies for adult asthma.
>Trial ID>Title>Status>Phase>Start Date>Summary
Showing 1 to 3 of 3 entries

Clinical Trial Conditions for TRIAMCINOLONE ACETONIDE

Condition Name

27131100510152025Diabetic Macular EdemaMacular EdemaAlopecia Areata[disabled in preview]
Condition Name for TRIAMCINOLONE ACETONIDE
Intervention Trials
Diabetic Macular Edema 27
Macular Edema 13
Alopecia Areata 11
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

58441900102030405060Macular EdemaEdemaMacular Degeneration[disabled in preview]
Condition MeSH for TRIAMCINOLONE ACETONIDE
Intervention Trials
Macular Edema 58
Edema 44
Macular Degeneration 19
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for TRIAMCINOLONE ACETONIDE

Trials by Country

+
Trials by Country for TRIAMCINOLONE ACETONIDE
Location Trials
United States 451
Canada 37
India 32
Egypt 28
China 20
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

+
Trials by US State for TRIAMCINOLONE ACETONIDE
Location Trials
California 32
Texas 27
Pennsylvania 25
Florida 23
New York 22
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for TRIAMCINOLONE ACETONIDE

Clinical Trial Phase

43.7%36.5%19.8%0-5051015202530354045505560Phase 4Phase 3Phase 2/Phase 3[disabled in preview]
Clinical Trial Phase for TRIAMCINOLONE ACETONIDE
Clinical Trial Phase Trials
Phase 4 55
Phase 3 46
Phase 2/Phase 3 25
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

63.8%18.6%17.6%0020406080100120CompletedUnknown statusRecruiting[disabled in preview]
Clinical Trial Status for TRIAMCINOLONE ACETONIDE
Clinical Trial Phase Trials
Completed 127
Unknown status 37
Recruiting 35
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for TRIAMCINOLONE ACETONIDE

Sponsor Name

trials02468101214National Eye Institute (NEI)Cairo UniversityClearside Biomedical, Inc.[disabled in preview]
Sponsor Name for TRIAMCINOLONE ACETONIDE
Sponsor Trials
National Eye Institute (NEI) 14
Cairo University 11
Clearside Biomedical, Inc. 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

74.6%20.1%5.3%0050100150200250OtherIndustryNIH[disabled in preview]
Sponsor Type for TRIAMCINOLONE ACETONIDE
Sponsor Trials
Other 253
Industry 68
NIH 18
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Triamcinolone Acetonide: Clinical Trials, Market Analysis, and Projections

Introduction to Triamcinolone Acetonide

Triamcinolone acetonide is a potent corticosteroid widely used for its anti-inflammatory and immunosuppressive properties. It is employed in various medical disciplines, including ophthalmology, dermatology, rheumatology, and allergy and respiratory medicine. Here, we will delve into the recent clinical trials, market analysis, and future projections for this versatile drug.

Clinical Trials Update

Suprachoroidal Delivery in Non-Infectious Uveitis

Recent clinical trials have focused on the suprachoroidal delivery of triamcinolone acetonide, particularly in the treatment of non-infectious uveitis. A multicenter real-world study presented at the American Society of Retina Specialists (ASRS) meeting highlighted the effect of this delivery method on intraocular pressure (IOP) in patients with a history of glaucoma, ocular hypertension, or steroid response. The study suggested that suprachoroidal triamcinolone acetonide may be safer in terms of IOP management compared to other corticosteroid implants like intravitreal dexamethasone or fluocinolone acetonide[1].

A pilot study by Goldstein et al. (2016) evaluated the safety, tolerability, and efficacy of a single suprachoroidal injection of triamcinolone acetonide in patients with non-infectious uveitis. The study found improvements in visual acuity and reductions in macular edema without significant increases in IOP, supporting further research in this area[4].

Phase 3 Trials: PEACHTREE and MAGNOLIA

The Phase 3 PEACHTREE trial involved 160 patients with macular edema due to non-infectious uveitis. Patients receiving suprachoroidal injections of triamcinolone acetonide showed significant improvements in best-corrected visual acuity (BCVA) and central subfield thickness compared to controls. The treatment was well-tolerated with no serious adverse events[4].

Market Analysis

Global Market Size and Growth

The global triamcinolone market is projected to grow significantly over the next decade. As of 2023, the market size was valued at $0.9 billion and is expected to reach $1.3 billion by 2033, growing at a Compound Annual Growth Rate (CAGR) of 3.8% from 2024 to 2033[2].

Key Drivers of Market Growth

Several factors are driving the growth of the triamcinolone market:

  • Increasing Prevalence of Chronic Diseases: Conditions such as asthma, arthritis, and allergies are becoming more common due to aging populations, unhealthy lifestyles, and environmental changes. Triamcinolone's effectiveness in managing these conditions contributes to its growing demand[2].
  • Rise in Geriatric Population: The aging population is more prone to chronic and inflammatory diseases, which increases the need for triamcinolone[2].
  • Expansion of Healthcare Infrastructure: Improved healthcare infrastructure and increased access to medical services also contribute to the market growth[2].

Market Segmentation

The triamcinolone market is segmented by type, application, distribution channel, and region. Key players in the market include Bristol Myers Squibb Company, Taro Pharmaceutical Industries, Teva Pharmaceuticals, and Novartis AG, among others[2].

Regional Insights

North America

North America is a dominant market for triamcinolone, driven by the presence of numerous pharmaceutical and dermatological companies. This region is expected to continue playing a significant role in the growth of the triamcinolone market[3].

Projections and Future Outlook

Market Size Projections

By 2030, the global market for triamcinolone acetonide injection is forecasted to reach $162.1 million, growing at a CAGR of 3.0% from 2024 to 2030[5].

Emerging Trends and Opportunities

  • Research and Development: Ongoing research and development in the use of triamcinolone acetonide, particularly in ophthalmology, are expected to open new avenues for its application.
  • Collaborations and Partnerships: Increasing partnerships among biopharmaceutical companies to expand their clinical pipeline of drugs will further drive the market growth[3].

Prescription Data and Usage

Triamcinolone is extensively prescribed across various medical disciplines due to its anti-inflammatory and immunosuppressive properties. It is commonly used in dermatology for conditions like eczema and psoriasis, in rheumatology for arthritis, and in allergy and respiratory medicine for asthma and allergic reactions. The injectable form is frequently used in orthopedic practices for joint pain and inflammation[2].

Key Takeaways

  • Clinical Trials: Suprachoroidal delivery of triamcinolone acetonide shows promise in treating non-infectious uveitis with favorable outcomes in terms of IOP management.
  • Market Growth: The global triamcinolone market is expected to grow significantly driven by the increasing prevalence of chronic diseases and the rise in the geriatric population.
  • Regional Dominance: North America remains a key market for triamcinolone due to the presence of major pharmaceutical companies.
  • Future Outlook: The market is projected to reach $1.3 billion by 2033, with ongoing research and development expected to expand its applications.

FAQs

What is the current market size of the triamcinolone market?

The global triamcinolone market size was valued at $0.9 billion in 2023[2].

What is the projected growth rate of the triamcinolone market from 2024 to 2033?

The triamcinolone market is expected to grow at a CAGR of 3.8% from 2024 to 2033[2].

Which regions are expected to drive the growth of the triamcinolone market?

North America is expected to be a dominant region driving the growth of the triamcinolone market[3].

What are the key applications of triamcinolone acetonide?

Triamcinolone acetonide is used in various medical disciplines including ophthalmology, dermatology, rheumatology, and allergy and respiratory medicine[2].

What are the major factors driving the growth of the triamcinolone market?

The growth is driven by the increasing prevalence of chronic diseases, the rise in the geriatric population, and the expansion of healthcare infrastructure[2].

Sources

  1. Modern Retina: ASRS 2024: The effect of suprachoroidal triamcinolone acetonide in non-infectious uveitis.
  2. Allied Market Research: Triamcinolone Market Statistics, Trends | Forecast - 2033.
  3. BioSpace: Atopic Dermatitis Clinical Trials Market Size to Increase USD 6.81 billion by 2033.
  4. Blue Care Network: SUPRACHOROIDAL DELIVERY OF PHARMACOLOGIC AGENT.
  5. Valuates Reports: Triamcinolone Acetonide Injection - Market Size.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.